These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 3330733)
1. [Hormone therapy and chemotherapy of endometrial cancer]. Lellouche D; Gairard B; Renaud R J Gynecol Obstet Biol Reprod (Paris); 1987; 16(6):773-80. PubMed ID: 3330733 [TBL] [Abstract][Full Text] [Related]
2. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma. Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103 [TBL] [Abstract][Full Text] [Related]
9. Nonhormonal chemotherapy in endometrial cancer--a review. Deppe G; Malviya VK; Zbella E Wien Klin Wochenschr; 1984 Oct; 96(20):747-56. PubMed ID: 6441352 [TBL] [Abstract][Full Text] [Related]
10. [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J Cancer Radiother; 2004 Jun; 8(3):155-67. PubMed ID: 15217583 [TBL] [Abstract][Full Text] [Related]
11. [An innovative protocol, cyclic hormone-chemotherapy in the treatment of high-risk localized endometrial cancer]. Audet-Lapointe P; Ayoub J; Methot Y J Gynecol Obstet Biol Reprod (Paris); 1988; 17(6):751-5. PubMed ID: 3209835 [No Abstract] [Full Text] [Related]
12. The management of patients with uterine sarcoma: a debated clinical challenge. Gadducci A; Cosio S; Romanini A; Genazzani AR Crit Rev Oncol Hematol; 2008 Feb; 65(2):129-42. PubMed ID: 17706430 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer. Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy in endometrial carcinoma: overview of randomised trials. Hogberg T Clin Oncol (R Coll Radiol); 2008 Aug; 20(6):463-9. PubMed ID: 18467080 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate. Piver MS Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011 [TBL] [Abstract][Full Text] [Related]
17. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
19. Stage III and oestrogen receptor negativity are associated with poor prognosis after adjuvant high-dose therapy in high-risk breast cancer. Hohaus S; Funk L; Martin S; Schlenk RF; Abdallah A; Hahn U; Egerer G; Goldschmidt H; Schneeweiss A; Fersis N; Kaul S; Wallwiener D; Bastert G; Haas R Br J Cancer; 1999 Mar; 79(9-10):1500-7. PubMed ID: 10188897 [TBL] [Abstract][Full Text] [Related]
20. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]